Adecatumumab
Based on 1 Customer Validation
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status.
For research use only. We do not sell to patients.
- Purity : 99.54%
- CAS No.: 503605-66-1
- Molecular Weight:147.52 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
EpCAM/TROP1/CD326
In Vitro
Adecatumumab (4 μM; 18 h) shows diverse kinetic binding activities among human Adecatumumab and murine Adecatumumab in B16/EpCAM 3E3 cells[2].
Adecatumumab (0.1 ng/mL-0.1 mg/mL; 4 h) shows a dose-dependent Antibodies depend on cell-mediated cytotoxicity (ADCC) activity in natural killing (NK) cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Both human adecatumumab and mu-adecatumumab (300 μg/mouse; i.v. bolus injection; single dose) exhibit a bi-exponential curve progression of serum concentration with an early distribution phase between 0 and 10 h and a terminal elimination phase[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female immunocompetent C57BL/6 mice (6-10 weeks old) with B16/EpCAM (i.v.)[2]
-
Dosage:250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab
-
Administration:250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab
-
Result:Both of them exhibited anti-tumor activity against B16/EpCAM cells in mice.
Although human adecatumumab inhibited the size of tumor colonies mice, the number of colonies was only slightly reduced after treatment without significant difference.
In contrast, mu-adecatumumab induced a highly significant reduction in the number of lung tumor colonies by >85%, and the few remaining tumor colonies were of very small size.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1.5×106 HT-29 cells labeling Adecatumumab (HY-P99278, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 503605-66-1
-
Appearance Liquid
-
Molecular Weight 147.52 kDa
-
Color Colorless to light yellow
-
SMILES
[Adecatumumab]
-
Synonyms
MT 201; Anti-Human EPCAM Recombinant Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kurtz JE, et al. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8. [Content Brief]
[2]. Lutterbuese P, et al. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother. 2007 Apr;56(4):459-68. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)